About us
At Spruce, we are guided by an unwavering commitment to patients and families living with serious, underserved neurological conditions. Time matters—and the need for safe and effective treatment is urgent and deeply personal.
For individuals living with MPS IIIB (Sanfilippo Syndrome Type B), and related conditions, current options are limited. That’s why we are advancing TA-ERT, our lead investigational therapy, with a clear goal: to move beyond conventional approaches by delivering outcomes not only measurable—but meaningful.
Guided by science and shaped by the voices of those affected, TA-ERT reflects our commitment to developing therapies that have the potential to meaningfully transform lives. Every decision we make is grounded in data, driven by empathy, and focused on the people who need us most. Their stories fuel our purpose. Their needs define our priorities.
Our Mission
Our mission at Spruce is to advance targeted, first-in-class therapies that address serious, underserved neurological conditions. At the heart of everything we do is our commitment to patients and their families. They inspire us to go beyond incremental progress to develop transformative therapies born from thoughtful science that leads to meaningful changes in their lives.
